Effective Colchicine Therapy for Recurrent Pericarditis
November 25, 2011 by Derek.
Inflammation of pericardium, the fibrous sac enclosing the heart, is a medical defect known as pericarditis. Patients often experience chest pain, swelling in the ankles and feet. Shortness of breath while lying down and anxiety are other symptoms. Our Canada pharmacy found more people purchase colchicine to prevent recurrent pericarditis.
Colchicine is an oral drug used to treat gout and familial Mediterranean fever (FMF) and is useful in suppressing inflammation. A recent trial now finds the prescription drug more effective than placebo in preventing recurrent and persistent symptoms of pericarditis in conjunction with conventional therapy. A double-blind multicenter randomized trial, the first of its kind, demonstrates effectiveness of the medication.
Trial Conducted To Verify Non-Randomized Observational Findings
Pericarditis has a common complication in that it is recurrent in about 20% to 50% cases of people who have experienced the medical condition earlier. Recurrent pericarditis is a disabling disease seriously affecting quality of life. Frequency at which it occurs makes re-hospitalization necessary. Efficient management is needed to keep treatment costs down. Open-label randomized studies conducted at two centers and non-randomized observational findings already revealed effectiveness of colchicine in preventing recurrent pericarditis. Experts were therefore of the opinion further tests were needed to verify results. Our Canada pharmacy followed up on the multi-center trial.
Experts from the European Society of Cardiology recommended colchicine in its 2004 guidelines for pericardial diseases, which initiated the CORP trial in four centers in Italy. The trial was conducted on 120 consecutive patients who experienced pericarditis for the first time. A primary endpoint was set up to check recurrence of pericarditis at the end of 18 months.
Several secondary endpoints were also set up. Recordings included checks to measure persistence of symptoms at the end of 72 hours, number of times the condition occurred, rate of remission at the end of the week, first recurrence, rate of constrictive pericarditis, cardiac tamponade, and hospitalization due to pericarditis.
Volunteers were given an initial dose of 1 to 2 mg on the day of starting the trial followed by 0.5 to 1 mg daily for the next six months. The lower initial and maintenance dozes were given to people below the rate of 70 kg and those who demonstrated intolerance to higher doses.
Positive Results Encourage Usage of Colchicine
Trial results clearly indicated colchicine was more effective than placebo. For example, the 18-month recurrence rate reduced by 55% in the case of colchicine compared to just 24% in the case of placebo. The mean number of recurrent episodes also reduced in favor of colchicine. At the end of 72 hours, persistent symptoms were 23% compared to 53.3% in placebo cases. Also, people found faster relief in 82% cases compared to 48% in people using placebo.
Colchicine is known to be a safe drug available at low cost at a Canada pharmacy. Further trials may be needed including people from other geographical locations and in more generalized settings; however, the prescription drug does provide rapid relief from symptoms of pericarditis. Its effectiveness over the 18-month period makes it an ideal medication to be added to empiric anti-inflammatory therapy for prevention of recurrent pericarditis.
Filed under: Colchicine Use, Recurrent Pericarditis.
Tags: colchicine, therapy, recurrent pericarditis, CORP, gout medication, buy colchicine.
Leave your comment: